• Corpus ID: 1629419

Multi-parameter Optimisation in Drug Discovery:

  title={Multi-parameter Optimisation in Drug Discovery:},
  author={Matthew D. Segall},
A high quality drug must exhibit a balance of many properties, including potency, ADME and safety. Identifying an optimal solution that balances multiple factors is known as ‘multi-parameter optimisation’ (MPO). In drug discovery this is particularly challenging due to complex, often conflicting property requirements combined with uncertain data because of experimental variability or predictive error. These make it difficult to decide with confidence which lines of enquiry to pursue and which… 

Figures from this paper



Beyond Profiling: Using ADMET Models to Guide Decisions

This work shows how models may be used to go ‘beyond profiling’ to guide key decisions in drug discovery, for example, selection of chemical series to focus resources with confidence or design of improved molecules targeting structural modifications to improve key properties.

The influence of drug-like concepts on decision-making in medicinal chemistry

Analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development.

How to improve R&D productivity: the pharmaceutical industry's grand challenge

A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity.

The Rule of Five for Non-Oral Routes of Drug Delivery: Ophthalmic, Inhalation and Transdermal

The Rule of Five should not be used to predict non-oral drug candidates, especially for inhalation and transdermal routes, and does appear to apply well to ophthalmic delivery.

"The desirability function: underlying assumptions and application implications"

  • Douglas N. FullerW. Scherer
  • Computer Science
    SMC'98 Conference Proceedings. 1998 IEEE International Conference on Systems, Man, and Cybernetics (Cat. No.98CH36218)
  • 1998
Critical issues that can arise from blind adherence to the concept of a "desirability function" are demonstrated.

Ligand efficiency: a useful metric for lead selection.

Multi-parameter optimization: identifying high quality compounds with a balance of properties.

  • M. Segall
  • Biology
    Current pharmaceutical design
  • 2012
How MPO can be applied to efficiently design and select high quality compounds is described and the range of methods that have been employed in drug discovery are described, including simple 'rules of thumb' such as Lipinski's rule; desirability functions; Pareto optimization; and probabilistic approaches that take into consideration the uncertainty in all drug discovery data due to predictive error and experimental variability.